(-0.47%) 4 987.71 points
(0.63%) 38 015 points
(-1.39%) 15 385 points
(0.83%) $83.42
(-0.46%) $1.749
(0.63%) $2 413.00
(1.36%) $28.77
(-1.19%) $943.10
(-0.08%) $0.939
(-0.19%) $11.02
(0.43%) $0.807
(-0.92%) $93.03
@ $35.47
Issued: 4 Mar 2024 @ 14:39
Return: -21.34%
Previous signal: Mar 1 - 13:21
Previous signal:
Return: -1.61 %
Live Chart Being Loaded With Signals
Immunovant, Inc., a clinical-stage biopharmaceutical company, develops monoclonal antibodies for the treatment of autoimmune diseases. It develops batoclimab, a novel fully human monoclonal antibody that selectively binds to and inhibits the neonatal fragment crystallizable receptor, which is in Phase IIa clinical trials for the treatment of myasthenia gravis and thyroid eye disease, as well as completed initiation of Phase II clinical trials for the treatment of warm autoimmune hemolytic anemia...
Stats | |
---|---|
Today's Volume | 401 756 |
Average Volume | 1.16M |
Market Cap | 4.05B |
EPS | $0 ( 2024-02-16 ) |
Next earnings date | ( $-0.430 ) 2024-05-27 |
Last Dividend | $0 ( N/A ) |
Next Dividend | $0 ( N/A ) |
P/E | -15.41 |
ATR14 | $0.0320 (0.11%) |
Date | Person | Action | Amount | type |
---|---|---|---|---|
2024-04-09 | Barnett Eva Renee | Sell | 3 689 | Common Stock |
2024-04-09 | Butchko Julia G. | Sell | 1 053 | Common Stock |
2024-04-09 | Salzmann Peter | Sell | 4 807 | Common Stock |
2024-04-02 | Fromkin Andrew J. | Buy | 11 255 | Common Stock |
2024-04-02 | Fromkin Andrew J. | Buy | 4 690 | Stock Option (right to buy) |
INSIDER POWER |
---|
85.11 |
Last 99 transactions |
Buy: 7 629 060 | Sell: 624 028 |
Volume Correlation
Immunovant Inc Correlation
10 Most Positive Correlations | |
---|---|
HZNP | 0.942 |
PMTS | 0.942 |
PEBK | 0.94 |
NWFL | 0.936 |
TBNK | 0.935 |
SNY | 0.935 |
WLFC | 0.934 |
ALOR | 0.931 |
MNKD | 0.925 |
LUNA | 0.925 |
10 Most Negative Correlations | |
---|---|
RPID | -0.941 |
USCB | -0.94 |
PCRX | -0.938 |
MEDS | -0.938 |
NKTX | -0.932 |
BOWXU | -0.931 |
QLGN | -0.93 |
STRC | -0.93 |
GOSS | -0.924 |
FATE | -0.924 |
Did You Know?
Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).
Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.
Immunovant Inc Correlation - Currency/Commodity
Immunovant Inc Financials
Annual | 2023 |
Revenue: | $0 |
Gross Profit: | $-1.32M (0.00 %) |
EPS: | $-1.710 |
Q4 | 2023 |
Revenue: | $0 |
Gross Profit: | $-341 000 (0.00 %) |
EPS: | $-0.460 |
Q3 | 2023 |
Revenue: | $0 |
Gross Profit: | $-333 000 (0.00 %) |
EPS: | $-0.490 |
Q2 | 2023 |
Revenue: | $0 |
Gross Profit: | $-327 000 (0.00 %) |
EPS: | $-0.410 |
Financial Reports:
No articles found.
Immunovant Inc
Immunovant, Inc., a clinical-stage biopharmaceutical company, develops monoclonal antibodies for the treatment of autoimmune diseases. It develops batoclimab, a novel fully human monoclonal antibody that selectively binds to and inhibits the neonatal fragment crystallizable receptor, which is in Phase IIa clinical trials for the treatment of myasthenia gravis and thyroid eye disease, as well as completed initiation of Phase II clinical trials for the treatment of warm autoimmune hemolytic anemia. The company was incorporated in 2018 is headquartered in New York, New York. Immunovant, Inc. is a subsidiary of Roivant Sciences Ltd.
About Live Signals
The live signals presented on this page help determine when to BUY or SELL NA. The signals have upwards of a 1-minute delay; like all market signals, there is a chance for error or mistakes.
The live trading signals are not definite, and getagraph.com hold no responsibility for any action taken upon these signals, as described in the Terms of Use. The signals are based on a wide range of technical analysis indicators